Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

Archives

Author Archives: Cathy Wilson
Aug 21, 2019Cathy WilsonNews

Preliminary Final Report and Full Year Accounts

21 August 2019 ASX Announcement Preliminary Final Report and Full Year Accounts   For the full report please click on the following link: Preliminary Final Report and Full Year Accounts

Read more
Jul 19, 2019Cathy WilsonNews

Penthrox USA Update

19 July 2019 ASX Announcement Penthrox – USA Update Medical Developments International Limited (ASX: MVP) advises that it met with the Food and Drug Administration (FDA) in mid-June 2019 in respect to its IND clinical hold letter issued in August 2018. For the full announcement, please click on the following link: Penthrox USA Update

Read more
Feb 20, 2019Cathy WilsonNews

MVP – Half Year Report and Accounts

20 February 2019 HALF-YEAR REPORT Pursuant to listing rule 4.2A, please find following Medical Developments International’s Consolidated Half-Year Report and associated results announcement, which should be read in conjunction with the most recent annual financial report. For a full copy of the Half-Year Report, please click on the following link: MDI FY19 HY Report and […]

Read more
Aug 29, 2018Cathy WilsonNews

Penthrox: USA update

29 August 2018 ASX Announcement Penthrox: USA update Medical Developments International Limited (ASX: MVP) advise that it has received correspondence from the USA Food & Drug Administration (FDA) in relation to its Investigative New Drug (IND) application to have Penthrox approved for sale in the United States of America. For the full release, please click […]

Read more
Aug 16, 2018Cathy WilsonNews

Preliminary Final Report and Full Year Accounts

17 August 2018 ASX Announcement Preliminary Final Report and Full Year Accounts   For the full report please click on the following link: Preliminary Final Report and Full Year Accounts

Read more
Aug 8, 2018Cathy WilsonNews

Capital Raising – Placement and Share Purchase Plan

8 August 2018 ASX ANNOUNCEMENT Capital Raising – Placement and Share Purchase Plan 1. Placement Medical Developments International (ASX: MVP) (Company) is pleased to advise that it has today successfully secured a placement of 4,250,000 ordinary shares in the Company to a number of sophisticated and wholesale investors at a price of $4.00 per share, […]

Read more
Aug 6, 2018Cathy WilsonNews

FY18 Results Update

For the full ASX Announcement “FY18 Results Update” please click on the following link:ASX Announcement – FY18 Results Update_060818

Read more
May 29, 2018Cathy WilsonNews

MVP signs exclusive Distribution Deal for Iran

29 May 2018 ASX Announcement MVP signs exclusive Distribution Deal for Iran. Penthrox approved in Romania, Bulgaria, Slovenia & Cyprus. Medical Developments International Limited (ASX: MVP) is delighted to announce that it has concluded an exclusive Distribution Deal with Nikkan Pharma, part of the Darman Ara group of companies.  Darman Ara is one of Iran’s […]

Read more
May 14, 2018Cathy WilsonNews

Trading Update

14 May 2018 ASX Announcement Trading Update Medical Developments International Limited (ASX: MVP) CEO, Mr. John Sharman, warned today that despite the fact that during FY18 Penthrox has been approved for sale in 15 additional countries including Canada, Germany, Mexico, Sweden and numerous other European countries, the upside from this global expansion will not be […]

Read more
Apr 27, 2018Cathy WilsonNews

Penthrox approved in Finland

24 April 2018 ASX Announcement Penthrox approved in Finland Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Finland.   For the full release, please refer to the following link: Penthrox approved in Finland

Read more
Page 1 of 5 : 12345

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter